Immitra Bio

Executive Summary

Immitra Bio is a Swiss biotechnology company founded in 2021 and headquartered in Basel. The company is developing a novel genetic medicine platform that combines hematopoietic stem cells (HSCs) with CRISPR-Cas9 gene editing to create precise and durable 'living drug' therapies for rare diseases, particularly those affecting children. By engineering a patient's own blood stem cells ex vivo, Immitra aims to provide curative treatments for conditions with high unmet medical needs. The company is currently in preclinical development, leveraging its proprietary gene-editing technology to address genetic disorders. With a focus on rare pediatric diseases, Immitra's approach has the potential to transform the treatment landscape by offering one-time, durable therapies. As a private, early-stage company, Immitra Bio is poised to advance its lead programs toward clinical validation in the coming years, pending financing and regulatory milestones.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data in a lead indication60% success
• Q4 2026Series A financing round50% success
• H1 2027IND/CTA filing for first-in-human study30% success